3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
5
Carcinoma, Transitional Cell
4
Ureteral Neoplasms
2
Urologic Neoplasms
1
Urethral Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Metastatic Urothelial Cancer and Other Malignant Solid Tumors
1
Metastatic Urothelial Cancer
1
Interventions
Gemcitabine
20
Cisplatin
13
Paclitaxel
8
Carboplatin
8
Docetaxel
5
Radiotherapy
4
Doxorubicin
4
aflibercept
3
Vinblastine
3
Ramucirumab
3
Methotrexate
3
Fluorouracil
3
vinflunine
2
pembrolizumab
2
Trastuzumab
2
Sunitinib
2
Platinum
2
Neoadjuvant Therapy
2
Ifosfamide
2
1,2-diaminocyclohexaneplatinum II citrate
2
vandetanib
1
tipifarnib
1
temsirolimus
1
rubitecan
1
piritrexim
1
pegfilgrastim
1
pazopanib
1
lonafarnib
1
ixabepilone
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Urethral Neoplasms
×
enfortumab vedotin
×
Clear all
NCT03219333
2024-08-27
EV-201
Astellas Pharma Inc
Phase 2
Completed
219 enrolled
32 charts
2 FDA